Search

Displaying results 1851 - 1860 of 10000 in total
  1. Target

    NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3

    go.drugbank.com/bio_entities/BE0000684
    TargetHumans

    Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

    Synonyms: Complex I-B9
  2. Target

    Dihydrolipoyl dehydrogenase

    go.drugbank.com/bio_entities/BE0002986
    TargetPseudomonas fluorescens

    The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2).

    Synonyms: E3 component of 2-oxoglutarate dehydrogenase complex
  3. Drug

    Disulfiram

    go.drugbank.com/drugs/DB00822
    ApprovedInvestigational

    A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol.

    Categories: Drugs Used in Alcohol Dependence, Drugs Used in Addictive DisordersSynonyms: N,N,N',N'-tetraethylthiuram disulfide, 1,1'-dithiobis(N,N-diethylthioformamide)
  4. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    [L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA … Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal

    Categories: Complex Mixtures
  5. Drug

    Quinidine

    go.drugbank.com/drugs/DB00908
    Approved

    This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. … A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.

    Categories: Compounds used in a research, industrial, or household setting, Complex Mixtures
  6. Drug

    Tiotropium

    go.drugbank.com/drugs/DB01409
    ApprovedInvestigational

    [A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation. … [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]

  7. Drug

    Metyrapone

    go.drugbank.com/drugs/DB01011
    ApprovedInvestigational

    An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

  8. Drug

    Glucarpidase

    go.drugbank.com/drugs/DB08898
    ApprovedInvestigational

    [L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE. … [L39855] High-dose [methotrexate], an antifolate agent, has been widely and safely used for many decades in treating various cancers; however, even with aggressive hydration, urine alkalinization, and

  9. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis. … [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis.

    Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE
  10. Drug

    1,2-Docosahexanoyl-sn-glycero-3-phosphoserine

    go.drugbank.com/drugs/DB11318
    Approved

    Synonyms: 1,2-Docosahexanoyl-sn-glycero-3-phosphoserineSalts: 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium